CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
The study will be conducted at the following locations:
1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan
Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.
Eligibility criteria
Qualifiers
Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
Adults 18 years old and above
Disqualifiers
Patients post liver transplantation
Patients with concurrent or prior HCC (LR-5 or biopsy proven)
other liver cancer including cholangiocarcinoma
Patients with any active extra-hepatic malignancy
Trial design
Treatments tested in this trial
- CEUS imaging
- aMRI imaging
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
University of Michigan
Collaborator
Source ClinicalTrials.gov